Related Experiment Videos
Juvenile idiopathic arthritis
Maria Espinosa1, Beth S Gottlieb
1The Steven and Alexandra Cohen Children's Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA.
Insights
Juvenile idiopathic arthritis (JIA) is a common childhood rheumatic disease. Early treatment and emerging genetic insights offer hope for improved diagnosis and targeted therapies, reducing long-term risks.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Genetics
Background:
- Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic condition in childhood.
- JIA is characterized by chronic inflammation with alternating periods of disease activity and remission.
- Current treatments include NSAIDs, corticosteroids, and methotrexate, with biologics used for severe cases and uveitis.
Purpose of the Study:
- To review the current understanding and management of Juvenile Idiopathic Arthritis.
- To highlight the potential of emerging genetic research in JIA diagnosis and treatment.
- To discuss the evolving landscape of JIA therapies, including biologics and future targeted approaches.
Main Methods:
- Literature review of JIA management strategies.
- Analysis of current therapeutic outcomes and safety profiles.
- Exploration of genetic research and its implications for JIA.
Main Results:
- Early and aggressive treatment significantly improves outcomes for most children with JIA.
- Biologics demonstrate safety and efficacy in aggressive JIA and uveitis, though long-term data is pending.
- Genetic testing holds promise for earlier diagnosis, disease course prediction, and personalized therapy.
Conclusions:
- Advances in treatment have improved JIA outcomes, but challenges remain.
- Genetic advancements are expected to revolutionize JIA diagnosis and treatment personalization.
- Future therapies aim for increased specificity to minimize immunosuppression and toxicity in JIA patients.
Abstract:
Juvenile idiopathic arthrithis (JIA) is the most common rheumatic disease of childhood.JIA is a chronic disease that is associated with periods of disease flares and periods of disease inactivity.Early, aggressive treatment with nonsteroidal anti-inflammatory drugs, intra-articular corticosteroid injections, or methotrexate, has significantly improved the outcome of most children who have JIA. Biologics have been shown to be both safe and effective for the treatment of more aggressive forms of arthritis and for uveitis. Long-term safety data of biologics is still uncertain. In the near future, it is hoped that genetic testing will allow earlier diagnosis of JIA as well as help predict the disease course of children who have JIA. Genetic analysis also may allow physicians to target therapies more effectively. It is hoped that development of more specific therapies will decrease overall immunosuppression and other associated toxicities.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
The JAK-STAT Signaling Pathway
Ankle Joint
Development of the Limb Synovial Joints
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
Chronic Inflammation: Introduction
Inflammatory Bowel Disease I: Introduction